— Facey K, Whittal A, Drummond M, Upadhyaya S, Junghans T, Nicod E.
Impact HTA. 2021.
Related articles
Why orphan medicines remain out of reach in low- and middle-income countries – and what can be done
Rare Diseases27/02/2026
Rare disease policy in high-income countries: An overview of achievements, challenges, and solutions
European PolicyRare DiseasesUS Policy10/05/2025
What do the new Medicare negotiations mean for pipeline orphan therapies?
Rare DiseasesUS Policy04/03/2025
Rare Disease Day 2025: How might JCA impact orphan sustainability in Europe?
JCARare Diseases28/02/2025